Analytical Data
-
Gene name
HLA-A*02:01&B2M&NY-ESO-1(SLLMWITQC) Monomer
- Application
-
Alternative Names
rHuHLA-A*0201 NY-ESO-1 complex Protein, His; MHC; MY-ESO-1; HLA-A*0201 NY-ESO-1 complex Protein
-
Species
Human
-
Source
HEK293
-
Tag
C-10*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01892 (G25-I308, A269V)&P61769
-
Expression Region
P01892 (G25-I308, A269V)&P61769 (I21-M119)&SLLMWITQC
-
AA Sequence
SLLMWITQC&IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM&GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQIMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQLRAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWVAVVVPSGEEQRYTCHVQHEGLPKPLTLRWELSSQPTIPI
-
Molecular Weight
55-60 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/NY-ESO-1 (SLLMWITQC) monomeric recombinant protein is rooted in the broader context of cancer immunotherapy and antigen presentation. NY-ESO-1 is a cancer/testis antigen frequently overexpressed in various malignancies, making it an attractive target for immunotherapeutic strategies. The HLA-A*02:01 molecule is a widely studied human leukocyte antigen (HLA) that plays a critical role in presenting peptide antigens to T cells, thereby initiating an immune response. The binding of the NY-ESO-1-derived peptide SLLMWITQC to HLA-A*02:01 is crucial for the activation of cytotoxic T lymphocytes (CTLs) that can recognize and eliminate cancer cells expressing this antigen. By producing a stable HLA-A*02:01/B2M/NY-ESO-1(SLLMWITQC) monomeric recombinant protein, researchers aim to elucidate the structural and functional dynamics of this peptide-HLA complex. This research can provide valuable insights into T cell receptor (TCR) recognition and specificity, potentially informing the development of advanced cancer vaccines and adoptive T cell therapies. The integration of insights gained from studying this monomer can advance our understanding of immune responses in cancer and enhance the design of targeted therapies that leverage the body’s immune system to fight tumors.
